SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Pacira Pharmaceuticals, Inc. to Contact Brower Piven Before the December 2, 2014 Lead Plaintiff Deadline in Class Action Lawsuit -- PCRX


STEVENSON, Md., Oct. 29, 2014 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Pacira Pharmaceuticals, Inc. ("Pacira" or the "Company") (Nasdaq:PCRX) securities during the period between April 9, 2012 and September 24, 2014, inclusive (the "Class Period"). Investors who wish to become proactively involved in the litigation have until December 2, 2014 to seek appointment as lead plaintiff.

If you have suffered a loss from investment in Pacira securities purchased on or after April 9, 2012 and held through the revelation of negative information during and/or at the end of the Class Period, as described below, and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at hoffman@browerpiven.com or by telephone at (410) 415-6616. No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.

If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action.  The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Company units during the Class Period. Brower Piven also encourages anyone with information regarding the Company's conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants' failure to disclose during the Class Period that that the Company improperly promoted EXPAREL as being able to work for up to 72 hours despite it being only approved for 24-hour pain relief, improperly claimed EXPAREL as safe and effective for use in cholecystectomy and colectomy, even though its approved labeling does not provide for such use and derived a substantial portion of its revenue from off label marketing.

According to the complaint, following the Company's September 25, 2014 revelation that it had received a Warning Letter from the U.S. Food and Drug Administration concerning the misleading marketing of EXPAREL and the misleading claims of efficacy, the value of Pacira shares declined significantly.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice.  You need take no action at this time to be a member of the class.



            

Contact Data